Granulomatosis with Polyangiitis Diagnosis and Management
Diagnosis
- The diagnosis of Granulomatosis with Polyangiitis (GPA) is established by the combination of clinical features, including upper respiratory tract involvement, lower respiratory tract involvement, and renal involvement, with elevated creatinine levels 1, 3
- Positive PR3-ANCA serology is present in 80-90% of GPA cases and is highly specific for this diagnosis, according to the European Vasculitis Study Group (EUVAS) criteria 1, 4
- Histopathological confirmation of GPA demonstrates necrotizing vasculitis of small arteries, granulomatous inflammation, and geographic necrosis 1, 2
- A negative ANA test helps exclude other autoimmune conditions like systemic lupus erythematosus, as recommended by the American College of Rheumatology 1
Renal Involvement
- The elevated serum creatinine indicates renal involvement from pauci-immune necrotizing crescentic glomerulonephritis, a hallmark manifestation of GPA, with a mechanism involving ANCA-mediated glomerulonephritis and necrotizing vasculitis of renal vessels 1, 4, 5, 6
- The renal involvement is classified as "generalized" or "severe" GPA according to the EUVAS criteria, with a high risk of progressive renal dysfunction and end-stage kidney disease 2
Treatment and Prognosis
- Without treatment, GPA has a mean survival of only 5 months, but with modern immunosuppressive therapy, mean survival has improved to 21.7 years from diagnosis, with a 10-year survival rate of approximately 40% when kidneys are involved, as reported by the European Vasculitis Study Group 7
- The treatment response is approximately 64% of patients achieving complete remission by 6 months, with a relapse risk of up to 50% of individuals, and mortality rates remaining at 5% or higher even with treatment, according to the American College of Rheumatology 7
- Staphylococcus aureus colonization is found in 72% of GPA patients and is strongly implicated in disease relapses, with prophylactic trimethoprim/sulfamethoxazole reducing relapse rates, as recommended by the Infectious Diseases Society of America 5, 6